N/A
Manufactured by AbbVie Inc.
28,252 FDA adverse event reports analyzed
Last updated: 2026-04-14
LOPINAVIR AND RITONAVIR is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by AbbVie Inc.. The most commonly reported adverse reactions for LOPINAVIR AND RITONAVIR include DRUG INTERACTION, DEPRESSION, DRUG EXPOSURE DURING PREGNANCY, DIARRHOEA, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LOPINAVIR AND RITONAVIR.
Out of 13,413 classified reports for LOPINAVIR AND RITONAVIR:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 28,252 FDA FAERS reports that mention LOPINAVIR AND RITONAVIR. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INTERACTION, DEPRESSION, DRUG EXPOSURE DURING PREGNANCY, DIARRHOEA, NAUSEA, FOETAL EXPOSURE DURING PREGNANCY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list AbbVie Inc. in connection with LOPINAVIR AND RITONAVIR. Always verify the specific product and NDC with your pharmacist.